BioMarin Pharmaceutical Inc. (BMRN)

Over the past six months, several events have impacted BioMarin Pharmaceutical, Inc.'s stock price. In March 2026, BioMarin halted dosing and enrollment in Phase 2 VOXZOGO trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency due to the occurrence of several slipped capital femoral epiphysis (SCFE) events, leading to a drop in shares. In February 2026, the company reported its Q4 and full-year 2025 financial results, exceeding revenue expectations but missing adjusted EPS estimates, and announced its strategic decision to voluntarily withdraw Roctavian from the market, resulting in approximately $240 million in charges. In December 2025, BioMarin announced the acquisition of Amicus Therapeutics for $4.8 billion, expected to close in Q2 2026, bolstering its rare genetic disease portfolio. In October 2025, BioMarin announced its decision to pursue options to divest Roctavian from its portfolio. In May 2025, the company reported strong Q1 2025 results with continued high demand for its medicines, leading to strong revenue growth and profitability, and shared positive top-line results from the Phase 3 PALYNZIQ study for adolescents with phenylketonuria, concluding enrollment in the pivotal study for VOXZOGO in hypochondroplasia. From March 24, 2025, to March 23, 2026, BioMarin's share price declined by 23.91%, trading between a 52-week high of $72.81 and a low of $50.76.

BioMarin's products generally experience continued high demand, with revenue increases driven by increased patient demand and the timing of large government orders. VOXZOGO has also shown strong global demand since its commercial launch in 2021. While the timing of large government orders can introduce some variability in quarterly revenues, there is no explicit information to suggest a significant or predictable seasonal pattern in the demand for BioMarin Pharmaceutical, Inc.'s products tied to specific times of the year.

BioMarin Pharmaceutical, Inc. is a global biotechnology company focused on developing and commercializing therapies for people with serious and life-threatening rare diseases and medical conditions, specializing in enzyme replacement therapies, gene therapies, and other advanced treatments for complex genetic disorders. BioMarin's core business and research are in enzyme replacement therapies (ERTs), and the company has a portfolio of eight commercial therapies, including Kuvan, Naglazyme, Aldurazyme, Firdapse, Vimizim, Brineura, Palynziq, and Voxzogo. Roctavian, a gene therapy for severe hemophilia A, was voluntarily withdrawn from the market in February 2026. BioMarin also has a clinical and preclinical pipeline, including Valoctocogene roxaparvovec (Roctavian), Vosoritide (Voxzogo), and BMN 307.

BioMarin Pharmaceutical Inc. is headquartered in San Rafael, California, U.S., and has offices and facilities across the United States, South America, Asia, and Europe. Key regional offices are located in Dublin, Ireland; Sao Paulo, Brazil; and Tokyo, Japan. The company also has a presence in Australia, Hong Kong, Taiwan, Greece, and Dubai. Manufacturing sites are located in Novato, California, and Shanbally, Ireland. BioMarin's commercial therapies reach patients in approximately 80 countries worldwide.

BioMarin has faced criticisms regarding drug pricing and specific instances of denying access to drugs in clinical trials. The discontinuation of dosing and enrollment in certain Phase 2 VOXZOGO trials and the voluntary withdrawal of Roctavian from the market could affect the company's reputation. Historically, BioMarin was involved in securities fraud class action lawsuits in 2020-2021 related to alleged misleading statements about the safety and prospects of its product candidate BMN 307 and the FDA approval process for Valrox, which have since been settled.

Institutional investors are the primary owners of BioMarin Pharmaceutical, Inc., holding the vast majority of its stock. As of May 2025, institutional investors collectively owned over 98% of BioMarin Pharmaceutical stock, increasing to 98.71% as of March 2026. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., PRIMECAP Management Company, Dodge & Cox, and Viking Global Investors LP. Insider ownership remains a small factor, ranging from 0.45% to 1.43% of the company's stock.